Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short-term Investments: 2009-2024

Historic Short-term Investments for Amicus Therapeutics (FOLD) over the last 15 years, with Dec 2024 value amounting to $36.2 million.

  • Amicus Therapeutics' Short-term Investments rose 354.93% to $73.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year increase of 354.93%. This contributed to the annual value of $36.2 million for FY2024, which is 7.68% down from last year.
  • Per Amicus Therapeutics' latest filing, its Short-term Investments stood at $36.2 million for FY2024, which was down 7.68% from $39.2 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Short-term Investments registered a high of $320.0 million during FY2020, and its lowest value of $36.2 million during FY2024.
  • Over the past 3 years, Amicus Therapeutics' median Short-term Investments value was $39.2 million (recorded in 2023), while the average stood at $73.4 million.
  • In the last 5 years, Amicus Therapeutics' Short-term Investments climbed by 3.27% in 2020 and then crashed by 72.92% in 2023.
  • Yearly analysis of 5 years shows Amicus Therapeutics' Short-term Investments stood at $320.0 million in 2020, then decreased by 25.85% to $237.3 million in 2021, then slumped by 38.99% to $144.8 million in 2022, then plummeted by 72.92% to $39.2 million in 2023, then dropped by 7.68% to $36.2 million in 2024.